Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Health Technology

Medical Supplies

Oncology

FLT3 ITD MRD Assay

More Like This

Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML

Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA

PR Newswire associated0

Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring

PR Newswire associated0

Advanced Method for Predicting Response to Midostaurin plus Chemotherapy in Acute Myeloid Leukaemia Greatly Outperforms Current Companion Diagnostic

VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

Diamyd Medical hits a recruitment milestone in DIAGNODE-3 Phase 3 trial